Get the Stockscreener App
458.28
0.31%
1.41
After Hours:
458.28
Alnylam Pharmaceuticals Inc stock is traded at $458.28, with a volume of 1.32M.
It is up +0.31% in the last 24 hours and up +42.98% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$456.87
Open:
$457
24h Volume:
1.32M
Relative Volume:
1.28
Market Cap:
$60.07B
Revenue:
$2.46B
Net Income/Loss:
$-319.09M
P/E Ratio:
-185.54
EPS:
-2.47
Net Cash Flow:
$-52.09M
1W Performance:
+6.59%
1M Performance:
+42.98%
6M Performance:
+82.94%
1Y Performance:
+66.96%
1-Day Range:
$450.88
$462.88
1-Week Range:
$421.81
$462.88
52-Week Range:
$205.87
$462.88
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
458.28 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.78 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.89 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.51 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Alnylam Pharmaceuticals' Insider Sales: Compliance-Driven Moves or Subtle Signals of Strategic Shift? - AInvest
Insider Selling at Alnylam Pharmaceuticals: A Closer Look at Implications for Investors - AInvest
Alnylam EVP Tanguler sells $632k in stock - Investing.com
Three Companies That Might Be Priced Below Their Estimated Value - simplywall.st
Insider Selling at Alnylam Pharmaceuticals: Profit-Taking or a Warning Sign? - AInvest
Alnylam Shares Surge on $730M Volume After FDA Approval Boosts Market Outlook and Analysts Raise Targets - AInvest
Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attentionWall Street Watch & Scalable Portfolio Growth Ideas - beatles.ru
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA - MSN
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth amid ATTR-CM market expansion - Investing.com
Free Genetic Tests May Aid People With Rare Kidney Disease - Medscape
Insider Selling Trends in Nasdaq-Listed Companies: A Cautionary Lens on Alnylam, Boston Scientific, and CSX - AInvest
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Alnylam Pharmaceuticals Inc. Reversal Rally May Surprise Bears2025 Market Overview & Technical Buy Zone Confirmations - beatles.ru
Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD By Investing.com - Investing.com Australia
Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD - Investing.com
Alnylam Gains 2.36% on FDA Support and Buy Rating as Top 500 Volume Strategy Yields 31.52% Return - AInvest
Alnylam Raises 2025 Revenue Guidance as Losses Widen Might Change The Case For Investing In ALNY - simplywall.st
Alnylam’s Trading Volume Surges 38.6% to Rank 113th in Market Activity - AInvest
Promising Biotech Stocks Worth WatchingAugust 12th - MarketBeat
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - 富途牛牛
Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attention [2025 Valuation Update]Low Risk Entry Point Tips - sisaissue.com
Alnylam’s $650M Volume Ranks 168th as Shares Drop 1.17% Pre-ESC Data Presentation - AInvest
Alnylam at Canaccord Genuity: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Alnylam at Canaccord Genuity: Strategic Growth and Innovation - Investing.com
Alnylam’s Vutrisiran Study: A Potential Game-Changer for Cardiomyopathy Treatment - TipRanks
Alnylam Pharmaceuticals at Canaccord Genuity's 45th Annual Growth Conference - AInvest
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 - BioSpace
Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock - Yahoo Finance
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Up 9.2% After Upward Q2 Revenue Guidance Revision and Higher Analyst Forecasts—Has the Bull Case Changed? - simplywall.st
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - ADVFN Brasil
Alnylam Gains 1.63% on Surging Amvuttra Sales Hits 233rd in Market Activity - AInvest
Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating - TipRanks
Does Alnylam’s (ALNY) Upbeat Revenue Forecast Signal Shifting Momentum in Its Long-Term Growth Story? - simplywall.st
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Alnylam Rises 2.2% on 17% Revenue Surge and Analyst Upgrades Despite 220th-Ranked 0.5B Volume Drop - AInvest
Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD - Investing.com
Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD By Investing.com - Investing.com Canada
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
Alnylam Slips 0.15% Despite $760M Volume Ranking 137th in U.S. Equities as Mixed Pipeline Data Weigh on Momentum - AInvest
Alnylam’s Amvuttra Sales Leave Forecasts In The Dust - Finimize
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference - Business Wire
Alnylam Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
Analyst Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher - Yahoo Finance
U.S. Transthyretin Amyloidosis Treatment Market Exclusive - openPR.com
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
Wolfe Research upgrades Alnylam Pharmaceuticals stock rating to Peerperform By Investing.com - Investing.com Canada
Oppenheimer upgrades Alnylam stock to Outperform on strong Amvuttra sales By Investing.com - Investing.com Canada
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain? - Yahoo Finance
Alnylam Pharmaceuticals Surges 3.79% Intraday – What’s Fueling This Sudden Rally? - AInvest
Alnylam's Amvuttra Sales Exceeding Expectations by Sizable Margin, Oppenheimer Says - MarketScreener
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ausiello Dennis A | Director |
Aug 14 '25 |
Option Exercise |
131.34 |
31,448 |
4,130,478 |
32,359 |
| Ausiello Dennis A | Director |
Aug 14 '25 |
Sale |
436.58 |
31,448 |
13,729,536 |
911 |
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):